Morgan Stanley
PGNX

Morgan Stanley’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Morgan Stanley’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q2 		– Sell
-670,371
Closed -$2.55M – 6847
2020
Q1 		$2.55M Buy
670,371
+130,865
+24% +$564K ﹤0.01% 3135
2019
Q4 		$2.75M Buy
539,506
+155,071
+40% +$820K ﹤0.01% 3780
2019
Q3 		$1.94M Sell
384,435
-103,301
-21% -$515K ﹤0.01% 3819
2019
Q2 		$3.01M Sell
487,736
-43,046
-8% -$208K ﹤0.01% 3425
2019
Q1 		$2.46M Buy
530,782
+126,209
+31% +$571K ﹤0.01% 3411
2018
Q4 		$1.7M Sell
404,573
-98,776
-20% -$503K ﹤0.01% 3902
2018
Q3 		$3.16M Sell
503,349
-432,472
-46% -$3.32M ﹤0.01% 3631
2018
Q2 		$7.52M Buy
935,821
+626,043
+202% +$4.78M ﹤0.01% 2699
2018
Q1 		$2.31M Buy
309,778
+71,420
+30% +$475K ﹤0.01% 3859
2017
Q4 		$1.42M Buy
238,358
+49,215
+26% +$299K ﹤0.01% 4313
2017
Q3 		$1.39M Buy
189,143
+70,684
+60% +$449K ﹤0.01% 4196
2017
Q2 		$804K Sell
118,459
-155,606
-57% -$1.15M ﹤0.01% 4523
2017
Q1 		$2.59M Sell
274,065
-102,821
-27% -$1.03M ﹤0.01% 3580
2016
Q4 		$3.26M Buy
376,886
+309,350
+458% +$2.29M ﹤0.01% 3432
2016
Q3 		$428K Buy
67,536
+43,884
+186% +$265K ﹤0.01% 4615
2016
Q2 		$100K Buy
23,652
+4,563
+24% +$22K ﹤0.01% 5243
2016
Q1 		$83K Buy
19,089
+2,559
+15% +$11.4K ﹤0.01% 5405
2015
Q4 		$101K Buy
16,530
+609
+4% +$3.99K ﹤0.01% 5399
2015
Q3 		$91K Sell
15,921
-47,504
-75% -$365K ﹤0.01% 5463
2015
Q2 		$474K Sell
63,425
-374,148
-86% -$2.26M ﹤0.01% 4752
2015
Q1 		$2.62M Buy
437,573
+17,866
+4% +$112K ﹤0.01% 3337
2014
Q4 		$3.17M Sell
419,707
-395,241
-48% -$2.36M ﹤0.01% 3162
2014
Q3 		$4.23M Sell
814,948
-35,456
-4% -$177K ﹤0.01% 2770
2014
Q2 		$3.67M Buy
850,404
+87,978
+12% +$336K ﹤0.01% 2958
2014
Q1 		$3.12M Buy
762,426
+40,181
+6% +$205K ﹤0.01% 3035
2013
Q4 		$3.85M Sell
722,245
-413,353
-36% -$1.82M ﹤0.01% 2811
2013
Q3 		$5.7M Buy
1,135,598
+105,022
+10% +$570K ﹤0.01% 2291
2013
Q2 		$4.6M Buy
+1,030,576
New +$4.62M ﹤0.01% 2410

Other funds holding PGNX

ECM
Everence Capital Management Goshen, Indiana $1.64B AUM 26.46% 1-Year Est. Return
New York State Teachers Retirement System (NYSTRS)
New York State Teachers Retirement System (NYSTRS) Albany, New York $49.2B AUM 29.3% 1-Year Est. Return
Daiwa Securities Group
Daiwa Securities Group Tokyo, Japan $34.8B AUM 20.7% 1-Year Est. Return

Morgan Stanley's PGNX Position: Q2 2020 in Review

Morgan Stanley sold out of Progenics Pharmaceuticals Inc (PGNX) in Q2 2020, closing a stake of 670,371 shares — an estimated $2.55M sold.

Morgan Stanley first reported a position in PGNX in Q2 2013 and held it in 28 quarters. The position peaked at $7.52M in Q2 2018. 3 funds tracked by Wall St. Rank hold PGNX as of Q2 2020.

  • Morgan Stanley reported no remaining Progenics Pharmaceuticals Inc position as of Q2 2020 after selling out during the quarter.
  • Morgan Stanley sold 670,371 Progenics Pharmaceuticals Inc shares in Q2 2020, an estimated $2.55M.
  • Morgan Stanley first reported a position in Progenics Pharmaceuticals Inc in Q2 2013 and held it in 28 quarters.
  • Morgan Stanley's Progenics Pharmaceuticals Inc position peaked at $7.52M in Q2 2018.
  • 3 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q2 2020.

Based on Morgan Stanley's 13F filing for Q2 2020, filed 14 Aug 2020.